WEIGHT LOSS

Switching Between GLP-1 Medications: Questions for Your Provider

People switch GLP-1 medications because of side effects, response, cost or access. There is no universal conversion chart, the labels advise against combining these drugs, and your prescriber sets the new starting point. Here are the questions worth asking.

By the NewDay Wellness editorial teamPublished October 25, 20266 min read7 sourcesMedically reviewed by Dr. Sean Arora and Dr. Shannon Arora on October 28, 2026

Switching from one GLP-1 medication to another is possible, but it is not a simple swap. Semaglutide and tirzepatide are different molecules, tablets and injections are not interchangeable milligram for milligram, compounded products vary in concentration, and the labels advise against using two of these drugs at once. That is why there is no universal conversion chart, and why the new starting point is a decision for your prescriber. This guide covers why people switch, what the research says, and the questions worth bringing to your next visit.

Key takeaways

• Common reasons for switching include side effects, a weaker response or plateau, cost, coverage and availability, or a preference for a different form.
• There is no official conversion chart between semaglutide and tirzepatide. Your prescriber chooses the starting dose and timing.
• Labels for Wegovy and Zepbound state that combining them with any other GLP-1 receptor agonist is not recommended, so switching generally means stopping one before starting the other.
• A gap in treatment can matter. The Wegovy label, for example, calls for restarting dose escalation after missing two or more consecutive doses.
• Moving between brand and compounded products, or between compounded products, deserves extra care with measurement, because the FDA has received reports of dosing errors.

Why people switch

The reasons fall into a few groups:

• Response. A 2026 study in Obesity looked at adults who moved from semaglutide to tirzepatide and classified their reasons as non-response (less than 5 percent weight reduction after at least three months) or a plateau after an initial response.
• Tolerability. Gastrointestinal effects top the list of common adverse reactions in these labels. The Zepbound label notes that most nausea, vomiting and diarrhea occurred during dose escalation.
• Cost, coverage and supply. A 2025 letter in Diabetes Care described how shortages and cost barriers pushed patients and clinicians to look for ways to keep therapy going, including transitions between GLP-1 medications.
• Form. Some people want to move from a weekly injection to a daily tablet, or the reverse.

Why there is no simple conversion

Several features of these medications make a one-to-one swap unreliable:

• Different molecules. Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both the GIP and GLP-1 receptors. Their dose ranges were developed separately.
• Different forms. The label shared by Rybelsus and Ozempic tablets states that those two tablet products are not interchangeable on a milligram basis, even though both contain semaglutide. Only a small fraction of oral semaglutide is absorbed, so tablet strengths are much larger by weight than injection strengths.
• Label-specific instructions. The Wegovy label does describe how to move between Wegovy injection and Wegovy tablets, with set timing between the last dose of one and the first dose of the other. That guidance applies to those two products only.
• Compounded concentrations. Compounded products are not FDA-approved and can be prepared at different concentrations. The FDA has reported dosing errors when patients measured and self-administered incorrect amounts.

What the research says

The best direct comparison of the two main medications is SURMOUNT-5, a 2025 trial in the New England Journal of Medicine. It randomized 751 adults with obesity and no diabetes to the highest tolerated dose of tirzepatide or semaglutide for 72 weeks. Average weight change was -20.2 percent with tirzepatide and -13.7 percent with semaglutide. This was a comparison between starting either drug, not a study of switching, and the trial was funded by the maker of tirzepatide.

Switching itself has mainly been studied in observational data. In the 2026 Obesity study, a retrospective review of adults treated with tirzepatide, 61 patients who switched from semaglutide because of non-response or a plateau saw an average additional weight reduction of 5.3 percent over six months. Those who switched at a plateau averaged 8.1 percent, while those who had not responded to semaglutide averaged 2.9 percent. The authors concluded that outcomes varied by prior response to semaglutide, weight-reduction status and diabetes status. These are small, non-randomized groups, so they show a pattern rather than a prediction. Your own response may be quite different.

Questions to ask your provider

Bringing specific questions makes the conversation more useful.

About the decision

• What is the main reason for switching in my case, and what would count as success?
• Is a dose adjustment or more time on my current medication a reasonable alternative?
• Is the new medication FDA-approved or compounded, and what does that mean for how it was reviewed?

About timing and the starting point

• When should I take my last dose of the current medication, and when should I start the new one?
• Will I start at a lower dose and work back up? Your prescriber decides this, and the answer often depends on how long it has been since your last dose.
• What should I do if there is a delay in receiving the new medication?

About safety

• Which side effects are most likely in the first weeks, and which ones should I report right away? The Zepbound label lists severe or persistent abdominal pain, signs of an allergic reaction and symptoms of dehydration among the problems that need prompt attention.
• If I use oral birth control, do I need a backup method? The Zepbound label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.
• Do any of my other medications need adjusting, especially insulin or other diabetes medicines?

About measurement

• If the product is a vial, exactly how much do I draw up, and in what units?
• Is the concentration of the new product different from the one I was using?

Frequently asked questions

Can I switch from semaglutide to tirzepatide?

Yes, prescribers do make this switch, and observational data suggest many people see additional weight change afterward, though results vary with how well they responded before. There is no official conversion, so your prescriber sets the starting dose and timing.

Can I take two GLP-1 medications at the same time to bridge the switch?

The Wegovy and Zepbound labels state that using them with another GLP-1 receptor agonist is not recommended. Overlapping is generally avoided. Ask your prescriber how to time the change.

Will I have to start over at the lowest dose?

Not always, but sometimes. It depends on the medications involved, your tolerance and how long you have been off treatment. The Wegovy label, for example, calls for restarting escalation after two or more missed doses in a row.

Can I move from the Wegovy injection to the Wegovy tablet?

The Wegovy label describes how a prescriber can move a patient between the injection and the tablet in either direction. The strengths are not interchangeable milligram for milligram, so follow your prescriber's specific instructions. See Oral and Injectable Semaglutide for how the two forms differ.

Talk to a licensed provider

A switch goes most smoothly when the reason is clear, the timing is planned and you know exactly how to measure the new medication. A licensed provider can review your history, side effects and goals and set a plan that fits. If you develop severe abdominal pain, trouble breathing or signs of a serious allergic reaction, call 911. This article is educational and does not determine eligibility for any treatment.

← Back to Health Guide